Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
System-State: Number of processed items 22.515 Notifications successully processed since Inception
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US44486Q1031
State: 10.01.2025 | 6PM
Do you already know our new terminal view? Click here.
FIGI: BBG00XPPT7S7
HUMA
Humacyte, Inc
GICS: - · Sector: - · Sub-Sector: -
NAME
Humacyte, Inc
ISIN
US44486Q1031
TICKER
HUMA
MIC
XNAS
REUTERS
HUMA.OQ
BLOOMBERG
HUMA US
Tue, 31.12.2024       Humacyte
US44486Q1031

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ:HUMA) securities between May 10, 2024, through October 17, 2024 (“the Class Period”). Investors ha...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Mon, 02.12.2024       Humacyte
US44486Q1031

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the North Carolina Middle District on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities during the period of May 10, 2024 to October 17, 2024, inclusive (“the Class Period...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Sun, 01.12.2024       Humacyte
US44486Q1031

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged vio...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Fri, 22.11.2024       Humacyte
US44486Q1031

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged viol...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Fri, 22.11.2024       Humacyte
US44486Q1031

Law Offices of Howard G. Smith reminds investors of the upcoming January 17, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Class Period”). Investors suffering los...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Thu, 21.11.2024       Humacyte
US44486Q1031

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Cl...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Wed, 20.11.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) and reminds investors of the January 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi &...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Wed, 20.11.2024       Humacyte
US44486Q1031

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Class Period”). Humacyte investors have until January 17, 2025...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Wed, 20.11.2024       Humacyte
US44486Q1031

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Invest...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Tue, 19.11.2024       Humacyte
US44486Q1031

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the North Carolina Middle District on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities during the period of May 10, 2024 to October 17, 2024, inclusive (“the Class Period”). Inve...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Tue, 19.11.2024       Humacyte
US44486Q1031

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024. Humacyte describes itself as a company that “engages in the development and manufacture of off-the-shelf, implantable, and bioengineer...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Tue, 19.11.2024       Humacyte
US44486Q1031

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Class Period”). Humacyte investors have until January 17, 2025 to file a lead plaintiff motion. ...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Mon, 18.11.2024       Humacyte
US44486Q1031

Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Middle District of North Carolina, captioned Cutshall v. Humacyte, Inc., et al., Case No. 1:24-cv-00954, on behalf of persons and entities that purchased or otherwise acquired Humacyte, Inc. (“Humacyte” or the “Co...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Wed, 06.11.2024       Humacyte
US44486Q1031

The Law Offices of Frank R. Cruz continues its investigation on behalf of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ:HUMA) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 9, 2024, after market hours, Hum...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Thu, 24.10.2024       Humacyte
US44486Q1031

The law firm of Kirby McInerney LLP is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). The investigation concerns whether Humacyte and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the inv...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Wed, 23.10.2024       Humacyte
US44486Q1031

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Humacyte inve...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Wed, 23.10.2024       Humacyte
US44486Q1031

Law Offices of Howard G. Smith announces an investigation on behalf of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) investors concerning the Company’s possible violations of federal securities laws. On August 9, 2024, after market hours, Humacyte disclosed that the FDA needed “additional time to complete its review of its Biologic ...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink
Wed, 23.10.2024       Humacyte
US44486Q1031

The Law Offices of Frank R. Cruz announces an investigation of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 9, 2024, after market hours, Humacyte disclos...
Read More
Humacyte
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.